Q3 2023 Orexo AB Earnings Call Transcript
This call is being recorded.
Welcome to Orexo Q3 report 2023.
(Operator Instructions) Now I will hand the conference over to CEO, Nikolaj Sørensen and CFO, Fredrik Järrsten. Please go ahead.
¸ -
Welcome to this third quarter call for Orexo. As most of you probably have seen, it's a mixed bag of news in the third quarter. We have had some good developments in several areas, but we also have some areas which have not really met our expectations for the quarter and where we've been a little disappointed.
The big thing for the quarter is, of course, the filing of OX124 in the US. It's rare in Sweden that pharmaceutical companies file for product for approval. And we're quite proud that we once again have filled. OX124 even though admittedly this time was a refiling, but relatively shortly after we received the notification from FDA that they didn't accept our first file.
As was said in the introduction, I'm joined by Fredrik Järrsten, who will go through the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
